Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loss of Response to Ustekinumab Treated by Dose Escalation
2018-004269-14Phase 4Completed
- Sponsor
- Belgian IBD research and development
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ustekinumab in Crohn's disease (2 arms), sponsored by Belgian IBD research and development. Primary endpoint: Steroid-free clinical remission with biochemical response. Started Sep 2019; status: completed.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2018-004269-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004269-14.